NEJM paper on selective reporting of trials of off-label use of gabapentin

This paper, published on Nov 12th, looked at 12 trials where both published reports and internal company documents on off label use of gabapentin (Neurontin) could be examined. The authors found that for "8 of the 12 reported trials, the primary outcome defined in the published report differed from that described in the protocol.", and go on to describe the types of differences found, including that "Of the 21 primary outcomes described in the protocols of the published trials, 6 were not reported at all and 4 were reported as secondary outcomes. Of 28 primary outcomes described in the published reports, 12 were newly introduced." The full paper requires a subscription; the abstract is freely available on the journal's website and in PubMed.